It was reported that the mutations that interested the transcription factors (e.g., RUNX1, CEBPA, GATA2) and activating signaling genes (e.g., FLT3, RAS family genes) were more common in MDS evolution to AML, considering that these variants were attained later during disorder progression in a subgroup of cells that extended [4]. This evidence concerns the gene FLT3 and acute myeloid leukemia.